Neovacs is developing new treatments for autoimmune diseases: Kinoid ®
Kinoid ® therapeutic vaccines allow the immune system to generate "natural" polyclonal antibodies, which can act against the overproduction of cytokines that cause the disease. Kinoids® are obtained by combining the targeted cytokine with a carrier protein, which makes it immunogenic.
In lupus, the Kinoids produce antibodies directed against the cytokine interferon alpha (IFNα). In asthma, Kinoids® produce antibodies directed against the cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13).

Kinoid injection to the patient induces natural polyclonal antibodies directed against different parts of the cytokine, neutralizing it more efficiently.

New programs are currently testing other autoantigens such as IgE.

Kinoid technology